Gene Therapy Advances, But Hemophilia is no Easy Target – Xconomy
Xconomy |
Gene Therapy Advances, But Hemophilia is no Easy Target
Xconomy One would think Skinner would jump at the chance, then, to try gene therapy, which offers the potential for a one-time long-lasting treatment—if not an outright cure. BioMarin Pharmaceutical (NASDAQ: BMRN) and Spark Therapeutics (NASDAQ: ONCE) are … Growth prospects of the Hemophilia Gene Therapy Market Analysis Report |
